Payment overview · 2025
General Payments
$203,317.62
189 reported records · 10 companies
Healthcare provider profile · identity verified
Nancy Ann Dawson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · WASHINGTON, DC · NPI 1073571519
Verified facts
What the public records show
CMS Open Payments records show Nancy Ann Dawson, M.D. received $203,317.62 in general payments during 2025 across 189 reported records.
Exelixis Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabometyx, Erleada, Nubeqa, Xtandi.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Xtandi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nubeqa as an associated drug or biological on 24369 records involving 9557 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Nubeqa by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
Exelixis Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABOMETYX as an associated drug or biological on 11749 records involving 4526 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Cabometyx by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Erleada by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 790 records involving 308 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Erleada by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 366 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exelixis Inc. | Unresolved — no canonical attribution shown | $54,302.58 | 26.7% | 63 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35,470.63 | 17.4% | 22 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33,212.09 | 16.3% | 21 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $30,527.98 | 15.0% | 38 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24,808.10 | 12.2% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $8,680.92 | 4.3% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $6,869.17 | 3.4% | 7 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $6,581.90 | 3.2% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $2,800.00 | 1.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $64.25 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,046.00 | 28 |
| Compensation for serving as faculty or as a speaker for a medical education program | $46,715.00 | 13 |
| Travel and Lodging | $33,723.01 | 105 |
| Consulting Fee | $15,280.25 | 8 |
| Food and Beverage | $2,553.36 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $54,302.58 | 63 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24,808.10 | 19 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $24,329.47 | 26 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $24,329.47 | 26 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $22,722.43 | 14 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $20,579.95 | 13 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $18,256.30 | 11 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $14,955.79 | 10 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $6,869.17 | 7 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $6,581.90 | 8 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $6,581.90 | 8 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $6,198.51 | 12 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $6,170.05 | 11 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $700.00 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $64.25 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABOMETYX cabometyx |
2025 | Cabometyx | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 115 | exact normalized | Medicare Part D |
| Nubeqa nubeqa |
2025 | Nubeqa | 2024 | 137 | exact normalized | Medicare Part D |
| Xtandi xtandi |
2025 | Xtandi | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
129 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Nubeqa open payments reported associated product |
CMS Open Payments — General Payments 24369 supporting records · 9557 recipient NPIs · example record 1225434669 |
Nubeqa · 2024 Exact normalized brand match · 1 Part D row |
137 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Exelixis Inc. Exact reporting entity; no affiliate inference |
2025 | CABOMETYX open payments reported associated product |
CMS Open Payments — General Payments 11749 supporting records · 4526 recipient NPIs · example record 1218789893 |
Cabometyx · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
115 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 790 supporting records · 308 recipient NPIs · example record 1174226359 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
115 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
366 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
129 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Orgovyx | Relugolix | 366 | 51 |
| Prednisone | Prednisone | 147 | 27 |
| Abiraterone Acetate | Abiraterone Acetate | 143 | 19 |
| Nubeqa | Darolutamide | 137 | 19 |
| Xtandi | Enzalutamide | 129 | 17 |
| Erleada | Apalutamide | 115 | 13 |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Bicalutamide | Bicalutamide | 27 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | 11 |
| Eliquis | Apixaban | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203,317.62 · 189 records | Exelixis Inc. | AKEEGA, CABOMETYX, CARVYKTI, ERLEADA, INVEGA SUSTENNA, INVEGA TRINZA, KEYTRUDA, Lenvima, Nubeqa, OPDIVO, PADCEV, RYBREVANT, TALZENNA, WELIREG, Xtandi | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabometyx play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error